跳至主要内容
临床试验/NCT05742087
NCT05742087进行中(未招募)不适用

Study of the Consequences of Anti-GFAP Antibodies on the Peripheral Nervous System

Hospices Civils de Lyon1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2022年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
120
试验地点
1
主要终点
Cranial nerves abnormality at clinical examination of abnormal ENMG

研究概览

简要总结

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts.

The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • - Age > 18 years old
  • Neurological symptoms
  • Anti-GFAP antibodies identified in the CSF

排除标准

  • - Uncomplete data in the medical records of patients

结局指标

主要结局

Cranial nerves abnormality at clinical examination of abnormal ENMG

时间窗: Immediately after diagnosis

Data concerning the clinical examination and the ENMG will be extracted from the cohort of patients with neurological syndroms and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes".

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验